Literature DB >> 3189923

Resistance to succinylcholine in myasthenia gravis: a dose-response study.

J B Eisenkraft1, W J Book, S M Mann, A E Papatestas, M Hubbard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3189923     DOI: 10.1097/00000542-198811000-00021

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  8 in total

Review 1.  Anaesthesia and myasthenia gravis.

Authors:  A Baraka
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

Review 2.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

Review 3.  Airway management in neurological emergencies.

Authors:  Lynn P Roppolo; Karina Walters
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 4.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 5.  Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  W J Book; M Abel; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

6.  A defasciculating dose of d-tubocurarine causes resistance to succinylcholine.

Authors:  J B Eisenkraft; M L Mingus; A Herlich; W J Book; A F Kopman
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

7.  Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca.

Authors:  Doron Feinsilber; Katrina A Mears; Brian L Pettiford
Journal:  Cureus       Date:  2017-06-20

8.  Myasthenic Crisis In Pregnancy.

Authors:  David M French; E Page Bridges; Matthew C Hoskins; Charles M Andrews; Cecil H Nelson
Journal:  Clin Pract Cases Emerg Med       Date:  2017-10-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.